The Science: A Nature-inspired Approach to Regrowing Your Own Hair
About Us
Developing novel treatments to address androgenic alopecia.
Amplifica is a biopharmaceutical company focused on developing novel treatments to address androgenic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The Company has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair. Amplifica will be initiating clinical trials to evaluate the safety and efficacy of its core technology as well as obtaining all applicable regulatory approvals.
Technology
Amplifica’s Science Based Approach.
Hair regrowth
Amplifica’s approach to hair regrowth is based on the discovery of naturally occurring signaling molecules that affect new hair growth.
Molecular biology
The scientific studies leading to the discovery of these molecules are based on the unique molecular biology found in the naturally occurring hairy nevi or “hairy moles” which has been extensively studied and uniquely understood by Amplifica.
Our Team
Meet the Amplifica Leadership Team.
Frank Fazio
President &
Chief Executive
Officer
Wajdie Ahmad
Co-Founder,
Executive Chairman
& COO
Maksim Plikus, PhD
Co-Founder &
Chief Scientific
Officer
William Rassman, MD
Co-Founder &
Chief Medical
Officer
Board of Directors
Meet the Amplifica Board of Directors.
News and Publications
Read our latest news.
Amplifica’s AMP-303 Study Unveils New Hope for Hair Loss Treatments
First-in-Human Trial Demonstrates Promising Results for the Treatment of Androgenetic Alopecia San Diego, CA, September 30, 2024 - Amplifica
Amplifica Announces First-in-Human Study Initiated
Amplifica’s AMP-303 safety and tolerability study targeting hair loss SAN DIEGO, CA., June 28, 2023 - Amplifica Holdings Group,
Nature Publication Reveals Cutting-Edge Advancements in Understanding Hair Growth
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage Protein SAN DIEGO, CA., June 21, 2023 - Amplifica Holdings
Amplifica Expands Pipeline for Hair Loss
Exclusive Licensing Agreement Allows for Access to Promising Early-Stage ProteinSAN DIEGO, CA., January 26, 2023 - Amplifica Holdings Group, Inc.
Contact Us